Page last updated: 2024-10-31

modafinil and Postoperative Complications

modafinil has been researched along with Postoperative Complications in 2 studies

Modafinil: A benzhydryl acetamide compound, central nervous system stimulant, and CYP3A4 inducing agent that is used in the treatment of NARCOLEPSY and SLEEP WAKE DISORDERS.
modafinil : A racemate comprising equimolar amounts of armodafinil and (S)-modafinil. A central nervous system stimulant, it is used for the treatment of sleeping disorders such as narcolepsy, obstructive sleep apnoea, and shift-work sleep disorder. The optical enantiomers of modafinil have similar pharmacological actions in animals.
2-[(diphenylmethyl)sulfinyl]acetamide : A sulfoxide that is dimethylsulfoxide in which two hydrogens attached to one of the methyl groups are replaced by phenyl groups, while one hydrogen attached to the other methyl group is replaced by a carbamoyl (aminocarbonyl) group.

Postoperative Complications: Pathologic processes that affect patients after a surgical procedure. They may or may not be related to the disease for which the surgery was done, and they may or may not be direct results of the surgery.

Research Excerpts

ExcerptRelevanceReference
"Modafinil significantly reduces fatigue and improves feelings of alertness and energy in postoperative patients."5.11Modafinil improves recovery after general anesthesia. ( Dunn, JB; Goldberg, ME; Hojat, M; Khaleghi, B; Larijani, GE; Marr, AT, 2004)
"Treatment with modafinil 400 mg per day was initiated on the 11th day after surgery and the patient's consciousness level rapidly improved on the 14th day."1.33Modafinil for the treatment of diminished responsiveness in a patient recovering from brain surgery. ( Rivera, VM, 2005)

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Larijani, GE1
Goldberg, ME1
Hojat, M1
Khaleghi, B1
Dunn, JB1
Marr, AT1
Rivera, VM1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Randomized, Double Blind, Placebo Controlled Evaluation of Modafinil vs Placebo for the Treatment of General Anesthesia Related Delayed Emergence in Patients With the Diagnosis of Obstructive Sleep Apnea[NCT02494102]Phase 4105 participants (Actual)Interventional2016-02-29Terminated
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Length of Time From Extubation to Discharge From Postanesthesia Recovery Unit

Length of time of above compared between groups (NCT02494102)
Timeframe: 24 hours

Interventionminutes (Mean)
Placebo53.5
Modafinil61.0

Postanesthesia Quality Recovery Scale Score

Postanesthesia quality recovery scale (PQRS). Component and aggregate scoring on the scale. Measures physiology, nociceptive, emotional activities of daily living cognitive and overall patient perspective. The scale is dimensionless and the aggregate of all individually tested dimensions is scaled from 17-65. A higher value implies improved postanesthesia recovery. Mean difference was assessed in each patient and aggregated thus patients with no difference between pre- and post-operative scores were zeroed (received a zero score if the difference was zero). A negative value was associated with worse outcome. (NCT02494102)
Timeframe: baseline and 6 hours after surgery

Interventionunits on a scale (Mean)
Placebo-5.67
Modafinil-8.91

Trials

1 trial available for modafinil and Postoperative Complications

ArticleYear
Modafinil improves recovery after general anesthesia.
    Anesthesia and analgesia, 2004, Volume: 98, Issue:4

    Topics: Adolescent; Adult; Aged; Ambulatory Surgical Procedures; Anesthesia Recovery Period; Anesthesia, Gen

2004

Other Studies

1 other study available for modafinil and Postoperative Complications

ArticleYear
Modafinil for the treatment of diminished responsiveness in a patient recovering from brain surgery.
    Brain injury, 2005, Aug-20, Volume: 19, Issue:9

    Topics: Aged; Benzhydryl Compounds; Brain; Central Nervous System Stimulants; Cerebral Ventricle Neoplasms;

2005